4-(哌啶-1-基磺酰基)苯甲酰氯 | 29171-75-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(哌啶-1-基磺酰基)苯甲酰氯
• 英文名称: 4-(1-piperidinylsulfonyl)benzoyl chloride
• 英文别名: 4-(Piperidin-1-ylsulfonyl)benzoyl chloride；4-piperidin-1-ylsulfonylbenzoyl chloride
• CAS: 29171-75-3
• 化学式: C₁₂H₁₄ClNO₃S
• 分子量: 287.767
• InChiKey: DTAXEYPEKABWAG-UHFFFAOYSA-N

物化性质

• 沸点：
  425.9±47.0 °C(Predicted)
• 密度：
  1.362±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  62.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险类别：
  8,6.1
• 危险性防范说明：
  P260,P264,P270,P271,P280,P301+P330+P331,P302+P352,P303+P361+P353,P304+P340,P305+P351+P338,P310,P403+P233,P405,P501
• 危险品运输编号：
  2923
• 危险性描述：
  H301,H311,H314,H331
• 包装等级：
  III

反应信息

• 作为反应物：
  描述：

  4-(哌啶-1-基磺酰基)苯甲酰氯 、 5-hydroxy-2-((pyrimidin-2-ylthio)methyl)-4H-pyran-4-one 在 caesium carbonate 作用下， 以 乙腈 为溶剂， 生成 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-(piperidin-1-ylsulfonyl)benzoate
  参考文献：
  名称：

  Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor

  摘要：

  The recently discovered apelin/APJ system has emerged as a critical mediator of cardiovascular homeostasis and is associated with the pathogenesis of cardiovascular disease. A role for apelin/APJ in energy metabolism and gastrointestinal function has also recently emerged. We disclose the discovery and characterization of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221), a potent APJ functional antagonist in cell-based assays that is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor. ML221 was derived from an HTS of the similar to 330,600 compound MLSMR collection. This antagonist showed no significant binding activity against 29 other GPCRs, except to the kappa-opioid and benzodiazepinone receptors (<50/<70%I at 10 mu M). The synthetic methodology, development of structure-activity relationship (SAR), and initial in vitro pharmacologic characterization are also presented. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.105
• 作为产物：
  描述：

  4-(哌啶-1-磺酰基)-苯甲酸 生成 4-(哌啶-1-基磺酰基)苯甲酰氯
  参考文献：
  名称：

  Discovery and initial development of a novel class of antibacterials: Inhibitors of Staphylococcus aureus transcription/translation

  摘要：

  The novel bacterial transcription/translation (TT) inhibitor 1 was identified through a combination of high throughput screening and exploratory medicinal chemistry. Initial optimization of the anthranilic acid moiety and sulfonamide amine diversity was accomplished via 1- and two-dimensional solution phase libraries, resulting in an improvement in the MIC of the lead from 64 to 8 mu g/mL (compound 4I). Subsequent modification of the central aromatic ring and further refinement of the sulfonamide amines required the development of a solid phase route on Wang resin. The resulting libraries generated a number of potent antibacterials with MICs of <= 1 mu g/mL (e.g., 10b, 12, and 13). During the course of this work, it became apparent that the antibacterial activity of the series is not fully correlated with TT inhibition, suggesting that at least one additional mechanism of action is operative. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.044

文献信息

• NEUROPROTECTIVE AMINOTHIAZOLES
  申请人：Dahl Russell

  公开号：US20200190078A1

  公开（公告）日：2020-06-18

  Disclosed herein are methods and compositions comprising compounds capable of activating and increasing protein SUMOylation. Disclosed herein are methods and compositions comprising compounds capable of showing neuroprotective and cytoprotective effects when administered to injured cells. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, chronic traumatic encepholopathy, traumatic brain injury, or stroke.

  本公开的方法和组合物包括能够激活和增加蛋白质SUMO化的化合物。本公开的方法和组合物包括能够在受伤细胞中给予神经保护和细胞保护效果的化合物。还公开了利用这些化合物治疗神经或神经系统疾病的方法，包括阿尔茨海默病、帕金森病、亨廷顿病、额颞叶痴呆、慢性创伤性脑病、创伤性脑损伤或中风。
• Neuroprotective aminothiazoles
  申请人：Dahl Russell

  公开号：US11220498B2

  公开（公告）日：2022-01-11

  Disclosed herein are methods and compositions comprising compounds capable of activating and increasing protein SUMOylation. Disclosed herein are methods and compositions comprising compounds capable of showing neuroprotective and cytoprotective effects when administered to injured cells. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, chronic traumatic encepholopathy, traumatic brain injury, or stroke.

  本文公开了包含能够激活和增加蛋白质 SUMOylation 的化合物的方法和组合物。本文公开了包含化合物的方法和组合物，这些化合物在给受伤细胞施用时能够显示出神经保护和细胞保护作用。还公开了包含这些化合物的治疗神经元或神经系统疾病的方法，包括阿尔茨海默病、帕金森病、亨廷顿病、前颞叶痴呆、慢性创伤性脑萎缩、脑外伤或中风。
• Discovery and initial development of a novel class of antibacterials: Inhibitors of Staphylococcus aureus transcription/translation
  作者：Scott D. Larsen、Matthew R. Hester、J. Craig Ruble、Gregg M. Kamilar、Donna L. Romero、Brian Wakefield、Earline P. Melchior、Michael T. Sweeney、Keith R. Marotti

  DOI：10.1016/j.bmcl.2006.09.044

  日期：2006.12

  The novel bacterial transcription/translation (TT) inhibitor 1 was identified through a combination of high throughput screening and exploratory medicinal chemistry. Initial optimization of the anthranilic acid moiety and sulfonamide amine diversity was accomplished via 1- and two-dimensional solution phase libraries, resulting in an improvement in the MIC of the lead from 64 to 8 mu g/mL (compound 4I). Subsequent modification of the central aromatic ring and further refinement of the sulfonamide amines required the development of a solid phase route on Wang resin. The resulting libraries generated a number of potent antibacterials with MICs of <= 1 mu g/mL (e.g., 10b, 12, and 13). During the course of this work, it became apparent that the antibacterial activity of the series is not fully correlated with TT inhibition, suggesting that at least one additional mechanism of action is operative. (c) 2006 Elsevier Ltd. All rights reserved.
• Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor
  作者：Patrick R. Maloney、Pasha Khan、Michael Hedrick、Palak Gosalia、Monika Milewski、Linda Li、Gregory P. Roth、Eduard Sergienko、Eigo Suyama、Eliot Sugarman、Kevin Nguyen、Alka Mehta、Stefan Vasile、Ying Su、Derek Stonich、Hung Nguyen、Fu-Yue Zeng、Arianna Mangravita Novo、Michael Vicchiarelli、Jena Diwan、Thomas D.Y. Chung、Layton H. Smith、Anthony B. Pinkerton

  DOI：10.1016/j.bmcl.2012.08.105

  日期：2012.11

  The recently discovered apelin/APJ system has emerged as a critical mediator of cardiovascular homeostasis and is associated with the pathogenesis of cardiovascular disease. A role for apelin/APJ in energy metabolism and gastrointestinal function has also recently emerged. We disclose the discovery and characterization of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221), a potent APJ functional antagonist in cell-based assays that is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor. ML221 was derived from an HTS of the similar to 330,600 compound MLSMR collection. This antagonist showed no significant binding activity against 29 other GPCRs, except to the kappa-opioid and benzodiazepinone receptors (<50/<70%I at 10 mu M). The synthetic methodology, development of structure-activity relationship (SAR), and initial in vitro pharmacologic characterization are also presented. (C) 2012 Elsevier Ltd. All rights reserved.